Getting to Complete Response With Less Toxicity in HER2-Positive Early Breast Cancer

(MedPage Today) -- In the DESTINY-Breast11 (DB11) trial, trastuzumab deruxtecan (T-DXd, Enhertu), followed by the taxane paclitaxel (Taxol), trastuzumab (Herceptin), and pertuzumab (Perjeta) in combination (THP), improved pathologic complete response...